New Hope for Liver Cancer: Abbisko Drug Gains Key EU Designation

SHANGHAI – March 31, 2026 – Patients with a hard-to-treat form of liver cancer have been given a significant boost of hope today. Abbisko Therapeutics announced that its investigational drug, irpagratinib, has been granted Orphan Drug Designation (ODD) by the European Medicines Agency (EMA). The designation targets its use in hepatocellular carcinoma (HCC), the most common type of primary liver cancer, and signals a major regulatory milestone that could accelerate the therapy's path to patients in Europe.

This key designation is reserved for medicines that treat rare, life-threatening, or chronically debilitating conditions. For Abbisko, a Shanghai-based biopharmaceutical company, the EMA's decision provides a powerful tailwind, offering benefits like protocol assistance, reduced regulatory fees, and, most critically, a potential 10 years of market exclusivity in the European Union following approval. It validates the drug's potential and strengthens the company's strategy to bring this innovative treatment to the global stage.

A Lifeline for a Challenging Cancer

Primary liver cancer is a formidable global health challenge, ranking as the third leading cause of cancer-related deaths worldwide. HCC accounts for the vast majority—approximately 75% to 85%—of these cases. While recent years have seen the rise of immune checkpoint inhibitors (ICIs) combined with anti-angiogenic therapies as the standard first-line treatment for advanced HCC, a significant portion of patients are left with limited options when the disease progresses or if they don't respond to initial treatments.

A critical unmet need exists within a specific subgroup of these patients. Roughly 30% of individuals with HCC have tumors that exhibit an overexpression of a protein called FGF19. This genetic characteristic is often linked to more aggressive disease and, crucially, a diminished benefit from the current standard-of-care immunotherapy combinations. To date, no approved therapy specifically targets the underlying biological driver in these patients—the FGFR4/FGF19 signaling pathway—leaving doctors with few effective tools for this population.

The Science of Precision: Targeting FGFR4

Irpagratinib (also known as ABSK-011) represents a new frontier in precision oncology for liver cancer. It is a highly selective, orally administered small-molecule inhibitor designed to shut down the activity of FGFR4, a receptor that, when activated by FGF19, fuels tumor cell growth and survival. By specifically targeting this pathway, irpagratinib aims to halt the cancer's progression with a tailored approach.

The drug's high selectivity is a key design feature, intended to maximize anti-tumor activity while minimizing the off-target side effects that can plague broader-spectrum inhibitors—a particularly important consideration for HCC patients who often have compromised liver function.

Early but compelling clinical data has bolstered confidence in this approach. In a Phase 1 study presented at the 2024 ESMO Congress, irpagratinib monotherapy demonstrated significant antitumor activity in heavily pretreated patients with FGF19-overexpressing advanced HCC. The trial reported an objective response rate (ORR) of 44.8% and a median progression-free survival (PFS) of 5.5 months, with a manageable safety profile.

More recent data from a Phase 2 study, presented at the 2025 ESMO GI Congress, explored irpagratinib in combination with the PD-L1 inhibitor atezolizumab. The results were even more striking, showing an ORR exceeding 50% and a median PFS of over 7 months in FGF19-overexpressing patients, including those who had previously been treated with immunotherapy. These findings suggest the combination could potentially restore or enhance the effectiveness of immunotherapy in this biomarker-defined population.

Navigating a Competitive Global Landscape

While irpagratinib's progress is promising, Abbisko is not alone in the race to target FGFR4. The pathway has been identified by several pharmaceutical companies as a valuable target in HCC. Competitors like Blueprint Medicines with its drug fisogatinib and Novartis with FGF401 are also advancing their own FGFR4 inhibitors through clinical trials. This competitive field underscores the scientific validity and commercial potential of this therapeutic strategy.

However, Abbisko holds a potential first-mover advantage. According to an analysis by Frost & Sullivan, irpagratinib is positioned to potentially become the first approved breakthrough treatment for HCC patients with FGF19 overexpression, as no FGFR4 inhibitor has yet secured regulatory approval anywhere in the world. The company's focused and rapid clinical development program aims to capitalize on this lead.

A Strategic Trifecta for Abbisko's Global Ambitions

The EMA's Orphan Drug Designation is the latest piece in a carefully constructed global regulatory puzzle for irpagratinib. This European milestone follows a series of similar strategic wins in other major markets. The drug has already been granted both Orphan Drug Designation and Fast Track Designation by the U.S. Food and Drug Administration (FDA), as well as Breakthrough Therapy Designation from China's National Medical Products Administration (NMPA).

This collection of designations forms a powerful global trifecta, creating expedited pathways for development and review in the world's three largest pharmaceutical markets. It reflects a concerted effort by Abbisko to synchronize its global development and position irpagratinib for worldwide access as quickly as possible. The company's solid financial footing, including recent profitability and a cash reserve of over RMB 2 billion, provides the necessary resources to support these ambitious late-stage clinical and commercialization efforts.

With a pivotal registrational study of irpagratinib monotherapy already enrolling patients across more than 50 clinical centers in China since June 2025, the company is making tangible progress toward its goal. By leveraging these regulatory advantages, Abbisko continues to aggressively advance its clinical programs, aiming to deliver a new, safe, and effective precision medicine to liver cancer patients who are waiting for a breakthrough.